GBA1 and Parkinson disease: In humans, another non-inhibitory small molecule compound (LTI-291) was tested in PD carriers of GBA mutations, showing positive safety, pharmacokinetic, and pharmacodynamic data but failing to demonstrate any benefit on neurocognitive outcomes [224].